FDA:- In a major advancement in paediatric healthcare, the United States Food and Drug Administration has approved the first prescription oral medicine for treating iron deficiency in children aged 10 years and above.
The decision broadens treatment options beyond dietary supplements and invasive therapies, addressing a widespread but often under-diagnosed health condition among school-age children and adolescents.
FDA Approves First Oral Iron Medicine for Children Aged 10 and Above
What the FDA Approval Covers
The FDA has approved Accrufer, an oral capsule containing ferric maltol, for paediatric patients aged 10 years and older diagnosed with iron deficiency.
Earlier, the medicine had been approved only for adult use since 2019. With this extension, doctors can now prescribe a regulated, prescription-grade oral iron therapy to children and teenagers who require medical treatment rather than dietary changes alone.
Why Iron Deficiency in Children Is a Serious Concern
Iron deficiency is the most common cause of anaemia worldwide. Iron is essential for producing haemoglobin, the protein responsible for transporting oxygen in the blood.
In children and adolescents, iron deficiency can lead to:
- Persistent fatigue
- Reduced attention and concentration
- Delayed physical growth
- Poor academic performance
Common causes include inadequate diet, poor absorption, chronic blood loss, and heavy menstrual bleeding in adolescents.
Clinical Evidence Behind the Approval
The FDA’s decision was based on findings from the FORTIS clinical trial, which included 24 patients aged 10–17 years.
Key trial outcomes:
- Accrufer administered twice daily for 12 weeks
- Average haemoglobin increase of 1.1 g/dL
- Improvement comparable to the effect of a single blood transfusion
- Achieved without injections or hospital-based procedures
Safety Profile and Limitations
Accrufer is not suitable for all patients. It is contraindicated in:
- Children with iron overload disorders (such as haemochromatosis)
- Patients receiving repeated blood transfusions
- Those allergic to its components
- Individuals with active inflammatory bowel disease
Common side effects include gastrointestinal discomfort, constipation or diarrhoea, nausea, vomiting, gas, and darkened stools.
Broader Significance of the Approval
The approval offers families a convenient, non-invasive, home-based treatment option, potentially reducing reliance on injections or transfusions. It also reflects increased regulatory attention to paediatric nutrition-related disorders, an area historically under-recognised despite its long-term health impact.
Exam-Oriented Key Facts
- FDA approved the first prescription oral iron medicine for children
- Applicable age group: 10 years and above
- Drug contains ferric maltol
- Iron deficiency is the leading cause of anaemia globally
- Approval based on the FORTIS clinical trial
- Oral therapy avoids injections and transfusions
Question & Answer
Q1. Which authority approved the first prescription oral medicine for iron deficiency in children?
(a) World Health Organization
(b) European Medicines Agency
(c) United States Food and Drug Administration
(d) National Institutes of Health
Answer: United States Food and Drug Administration
Q2. The newly approved oral iron medicine for children contains which compound?
(a) Ferrous sulphate
(b) Ferric maltol
(c) Iron dextran
(d) Haem iron
Answer: Ferric maltol
Q3. The FDA approval for the oral iron medicine applies to children of which age group?
(a) Below 5 years
(b) 6–9 years
(c) 10 years and above
(d) All age groups
Answer: 10 years and above
Q4. Iron deficiency mainly affects the production of which blood component?
(a) Platelets
(b) Plasma
(c) White blood cells
(d) Haemoglobin
Answer: Haemoglobin
Q5. The paediatric approval of the oral iron medicine was based on which clinical trial?
(a) IRON-KIDS trial
(b) PAED-IRON trial
(c) FORTIS trial
(d) HEMO-CARE trial
Answer: FORTIS trial
🔗 Other Useful Links:
📌 Latest Government Job Vacancies
📌 Latest Exam Results
📌 Free Mock Tests
.jpg=w704-h396-p-k-no-nu?w=1024&resize=1024,1024&ssl=1 "HSBC Appoints Brendan Nelson as New Chairman: Key Facts on Successor and Strategic Focus on Asia")
.jpg=w704-h396-p-k-no-nu?w=1024&resize=1024,1024&ssl=1 "India Pushes for Global Partnership in Critical Minerals at Jamshedpur Conference")
.jpg=w704-h396-p-k-no-nu?w=1024&resize=1024,1024&ssl=1 "Mizoram Launches GBV Solve Project to Combat Gender-Based Violence and Empower Women")
.jpg=w704-h396-p-k-no-nu?w=1024&resize=1024,1024&ssl=1 "Tamil Nadu Develops Aerospace Hub Near New ISRO Launch Site at Kulasekarapattinam")